Other Events ·
Liquidia settles all litigation with United Therapeutics, agreeing to pay net $380.7 million
LQDALiquidia Corp
Liquidia Corporation and its subsidiary entered into a global settlement agreement with United Therapeutics to resolve all pending patent infringement, trade secret, breach of contract, and antitrust litigations. Under the terms, Liquidia will make a net payment of $175 million within 30 days and pay an additional $145.4 million in two installments by April 2027. The company also paid $60.3 million to settle interests held by Sandoz, Henderson SPV, and PBM RG Holdings regarding the antitrust proceedings. In exchange for these payments, Liquidia will remove the PH-ILD indication from its YUTREPIA label and cease promotion for that use, while retaining rights to market YUTREPIA for pulmonary arterial hypertension (PAH). The settlement includes mutual releases of claims and dismissals with prejudice. Liquidia reported preliminary Q3 2026 YUTREPIA net sales of $222.7 million and cash holdings of $396.1 million as of September 30, 2026. Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing products for respiratory and vascular diseases using its proprietary PRINT technology.